2-Arachidonoylglycerol: A novel inhibitor of androgen-independent prostate cancer cell invasion

Kasem Nithipatikom, Michael P. Endsley, Marilyn A. Isbell, J R Falck, Yoshiki Iwamoto, Cecilia J. Hillard, William B. Campbell

Research output: Contribution to journalArticle

100 Scopus citations

Abstract

Endocannabinoids have been implicated in cancer. Increasing endogenous 2-arachidonoylglycerol (2-AG) by blocking its metabolism inhibits invasion of androgen-independent prostate cancer (PC-3 and DU-145) cells. Noladin ether (a stable 2-AG analog) and exogenous CB1 receptor agonists possess similar effects. Conversely, reducing endogenous 2-AG by inhibiting its synthesis or blocking its binding to CB1 receptors with antagonists increases the cell invasion. 2-AG and noladin ether decrease protein kinase A activity in these cells, indicating coupling of the CB1 receptor to downstream effectors. The results suggest that cellular 2-AG, acting through the CB1 receptor, is an endogenous inhibitor of invasive prostate cancer cells.

Original languageEnglish (US)
Pages (from-to)8826-8830
Number of pages5
JournalCancer research
Volume64
Issue number24
DOIs
StatePublished - Dec 15 2004

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of '2-Arachidonoylglycerol: A novel inhibitor of androgen-independent prostate cancer cell invasion'. Together they form a unique fingerprint.

  • Cite this

    Nithipatikom, K., Endsley, M. P., Isbell, M. A., Falck, J. R., Iwamoto, Y., Hillard, C. J., & Campbell, W. B. (2004). 2-Arachidonoylglycerol: A novel inhibitor of androgen-independent prostate cancer cell invasion. Cancer research, 64(24), 8826-8830. https://doi.org/10.1158/0008-5472.CAN-04-3136